Please see our CAB-LA newsletters here, and here which include a summary of key updates and news surrounding long-acting cabotegravir (CAB-LA), including information presented at the recent 24th International AIDS Conference in Montreal and the next steps which follow the announcement of the voluntary licensing agreement between ViiV Healthcare and the Medicines Patent Pool for long-acting cabotegravir patents.

This new bi-weekly newsletter will summarise key developments relating to long-acting injectable cabotegravir (CAB-LA) and HIV prevention.